Christian Schwiebert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christian Schwiebert has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Lutz Schomburg
Institute for Experimental Endocrinology Charité‐Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität Zu Berlin, and Berlin Institute of Health Berlin Germany
5 shared publications - Eike Christian Kühn
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
2 shared publications Tim Welsink
2 shared publications- Waldemar B. Minich
Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany
2 shared publications Waldemar Minich
2 shared publicationsAlbrecht Schmidt
1 shared publication
Latest Publications
- Open Access
- 11 January 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (2) , 463
Antagonistic Autoantibodies to Insulin-Like Growth Factor-1 Receptor Associate with Poor Physical Strength
Natural autoantibodies to the IGF1 receptor (IGF1R-aAb) have been described in relation to Graves’ ophthalmopathy. Other physiological roles of natural IGF1R-aAb are not known. We hypothesized that IGF1R-aAb may be related to muscle development. Serum samples (n = 408) from young overweight subjects (n = 143) were collected during a lifestyle intervention study. Anthropometric parameters, along with leptin, IGF1 and IGF1R-aAb concentrations, were analyzed, and the subjects were categorized into positive or negative for IGF1R-aAb. Eleven out of 143 subjects (7.7%) were positive for IGF1R-aAb. Identified IGF1R-aAb were molecularly characterized and showed antagonistic activity in vitro impairing IGF1-mediated IGF1R activation. Mean body weight, height or age were similar between IGF1R-aAb-positive and -negative subjects, but IGF1 concentrations differed. Jumping ability, as well as right and left handgrip strengths, were lower in the IGF1R-aAb-positive as compared to the IGF1R-aAb-negative subjects. We conclude that natural IGF1R-aAb are detectable in apparently healthy subjects and are capable of antagonizing IGF1-dependent IGF1R activation. Moreover, the presence of IGF1R-aAb is associated with poor physical strength. Although the causality of this association is unclear, the data imply a potential influence of IGF1R autoimmunity on muscle development.
- 11 January 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (2) , 463
Open AccessAntagonistic Autoantibodies to Insulin-Like Growth Factor-1 Receptor Associate with Poor Physical Strength
Natural autoantibodies to the IGF1 receptor (IGF1R-aAb) have been described in relation to Graves’ ophthalmopathy. Other physiological roles of natural IGF1R-aAb are not known. We hypothesized that IGF1R-aAb may be related to muscle development. Serum samples (n = 408) from young overweight subjects (n = 143) were collected during a lifestyle intervention study. Anthropometric parameters, along with leptin, IGF1 and IGF1R-aAb concentrations, were analyzed, and the subjects were categorized into positive or negative for IGF1R-aAb. Eleven out of 143 subjects (7.7%) were positive for IGF1R-aAb. Identified IGF1R-aAb were molecularly characterized and showed antagonistic activity in vitro impairing IGF1-mediated IGF1R activation. Mean body weight, height or age were similar between IGF1R-aAb-positive and -negative subjects, but IGF1 concentrations differed. Jumping ability, as well as right and left handgrip strengths, were lower in the IGF1R-aAb-positive as compared to the IGF1R-aAb-negative subjects. We conclude that natural IGF1R-aAb are detectable in apparently healthy subjects and are capable of antagonizing IGF1-dependent IGF1R activation. Moreover, the presence of IGF1R-aAb is associated with poor physical strength. Although the causality of this association is unclear, the data imply a potential influence of IGF1R autoimmunity on muscle development.
- Open Access
Selenium-Binding Protein 1 Indicates Myocardial Stress and Risk for Adverse Outcome in Cardiac Surgery
Selenium-binding protein 1 (SELENBP1) is an intracellular protein that has been detected in the circulation in response to myocardial infarction. Hypoxia and cardiac surgery affect selenoprotein expression and selenium (Se) status. For this reason, we decided to analyze circulating SELENBP1 concentrations in patients (n = 75) necessitating cardioplegia and a cardiopulmonary bypass (CPB) during the course of the cardiac surgery. Serum samples were collected at seven time-points spanning the full surgical process. SELENBP1 was quantified by a highly sensitive newly developed immunological assay. Serum concentrations of SELENBP1 increased markedly during the intervention and showed a positive association with the duration of ischemia (ρ = 0.6, p < 0.0001). Elevated serum SELENBP1 concentrations at 1 h after arrival at the intensive care unit (post-surgery) were predictive to identify patients at risk of adverse outcome (death, bradycardia or cerebral ischemia, “endpoint 1”; OR 29.9, CI 3.3–268.8, p = 0.00027). Circulating SELENBP1 during intervention (2 min after reperfusion or 15 min after weaning from the CPB) correlated positively with an established marker of myocardial infarction (CK-MB) measured after the intervention (each with ρ = 0.5, p < 0.0001). We concluded that serum concentrations of SELENBP1 were strongly associated with cardiac arrest and the duration of myocardial ischemia already early during surgery, thereby constituting a novel and promising quantitative marker for myocardial hypoxia, with a high potential to improve diagnostics and prediction in combination with the established clinical parameters.
Open AccessSelenium-Binding Protein 1 Indicates Myocardial Stress and Risk for Adverse Outcome in Cardiac Surgery
Selenium-binding protein 1 (SELENBP1) is an intracellular protein that has been detected in the circulation in response to myocardial infarction. Hypoxia and cardiac surgery affect selenoprotein expression and selenium (Se) status. For this reason, we decided to analyze circulating SELENBP1 concentrations in patients (n = 75) necessitating cardioplegia and a cardiopulmonary bypass (CPB) during the course of the cardiac surgery. Serum samples were collected at seven time-points spanning the full surgical process. SELENBP1 was quantified by a highly sensitive newly developed immunological assay. Serum concentrations of SELENBP1 increased markedly during the intervention and showed a positive association with the duration of ischemia (ρ = 0.6, p < 0.0001). Elevated serum SELENBP1 concentrations at 1 h after arrival at the intensive care unit (post-surgery) were predictive to identify patients at risk of adverse outcome (death, bradycardia or cerebral ischemia, “endpoint 1”; OR 29.9, CI 3.3–268.8, p = 0.00027). Circulating SELENBP1 during intervention (2 min after reperfusion or 15 min after weaning from the CPB) correlated positively with an established marker of myocardial infarction (CK-MB) measured after the intervention (each with ρ = 0.5, p < 0.0001). We concluded that serum concentrations of SELENBP1 were strongly associated with cardiac arrest and the duration of myocardial ischemia already early during surgery, thereby constituting a novel and promising quantitative marker for myocardial hypoxia, with a high potential to improve diagnostics and prediction in combination with the established clinical parameters.
- 1 March 2019
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 52, 247-253
Circulating levels of selenium-binding protein 1 (SELENBP1) are associated with risk for major adverse cardiac events and death
- 1 March 2019
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 52, 247-253
Circulating levels of selenium-binding protein 1 (SELENBP1) are associated with risk for major adverse cardiac events and death
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Association of IGF1 receptor autoantibodies with height and body size
Objective: Insulin-like growth factor 1 (IGF1) has a crucial role in growth and metabolism. A specifically designed autoantibody (aAb) assay against the IGF1 receptor (IGF1R-aAb) is able to detect IGF1R-aAb in serum. As the IGF1R has shown involvement in many functional pathologies (e.g. in the Laron syndrome), we aimed to investigate the role of IGF1R-aAb in a large population-based cohort of middle-aged volunteers and their potential effects on anthropometric, osteological and metabolic characteristics. Methods: Clinical and biochemical parameters of 966 volunteers (531 female and 435 male) of the BioPersMed cohort (Biomarkers in Personalized Medicine, Medical University Graz) were analysed to identify putative differences between IGF1R-aAb positive (binding index >3 – times above background) and control subjects. Laboratory data in combination with DXA-derived measurements of bone density, dimensions and body composition allowed a detailed insight into the relation of IGF1R-aAb with biomarkers (body height and composition, hormones and metabolic factors). Unpaired 2 tailed T-test was used to test for statistical significance. Results: Mean age of the cohort was 57.7 years±8.1 years for women and 58.4 years±9.0 years for men. IGF1R-aAbs were identified in 6.0% of all volunteers (7.6% female and 5.2% male). IGF1R-aAb positive volunteers showed significantly different bone density (P=0.001), body composition (P=0.012) and a significant increase in body height [+4.1 cm in men (P=0.002) and +1.6 cm in women (P=0.1)], with a more pronounced effect in men. There was no difference in age or BMI between the groups. Summary and conclusions: IGF1R-aAbs are relatively prevalent in healthy adult humans and may affect body height by modulating bone growth. However, their origin, regulation, and relation to hormonal and metabolic pathways have not yet been fully clarified. Therefore, research and monitoring of IGF1R-aAb prevalence before puberty and during lifetime of women and men is a compelling approach but the mechanisms around IGF1R- aAbs and their potential effects remains to be elucidated.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Association of IGF1 receptor autoantibodies with height and body size
Objective: Insulin-like growth factor 1 (IGF1) has a crucial role in growth and metabolism. A specifically designed autoantibody (aAb) assay against the IGF1 receptor (IGF1R-aAb) is able to detect IGF1R-aAb in serum. As the IGF1R has shown involvement in many functional pathologies (e.g. in the Laron syndrome), we aimed to investigate the role of IGF1R-aAb in a large population-based cohort of middle-aged volunteers and their potential effects on anthropometric, osteological and metabolic characteristics. Methods: Clinical and biochemical parameters of 966 volunteers (531 female and 435 male) of the BioPersMed cohort (Biomarkers in Personalized Medicine, Medical University Graz) were analysed to identify putative differences between IGF1R-aAb positive (binding index >3 – times above background) and control subjects. Laboratory data in combination with DXA-derived measurements of bone density, dimensions and body composition allowed a detailed insight into the relation of IGF1R-aAb with biomarkers (body height and composition, hormones and metabolic factors). Unpaired 2 tailed T-test was used to test for statistical significance. Results: Mean age of the cohort was 57.7 years±8.1 years for women and 58.4 years±9.0 years for men. IGF1R-aAbs were identified in 6.0% of all volunteers (7.6% female and 5.2% male). IGF1R-aAb positive volunteers showed significantly different bone density (P=0.001), body composition (P=0.012) and a significant increase in body height [+4.1 cm in men (P=0.002) and +1.6 cm in women (P=0.1)], with a more pronounced effect in men. There was no difference in age or BMI between the groups. Summary and conclusions: IGF1R-aAbs are relatively prevalent in healthy adult humans and may affect body height by modulating bone growth. However, their origin, regulation, and relation to hormonal and metabolic pathways have not yet been fully clarified. Therefore, research and monitoring of IGF1R-aAb prevalence before puberty and during lifetime of women and men is a compelling approach but the mechanisms around IGF1R- aAbs and their potential effects remains to be elucidated.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Autoantibodies to the insulin- and IGF1-receptor in human sera
Introduction: Autoantibodies (aAB) are characteristic of autoimmune diseases, but may also be found in apparently healthy individuals and precede pathological symptoms. We have recently reported on autoantibodies against the IGF1-receptor (IGF1R-aAB) in control subjects and patients with Graves’ disease (1). The isolated aAB were able to immunoprecipitate the recombinant autoantigen and antagonized IGF1 signaling in vitro. Given the structural similarities between IGF1R and insulin receptor (IR), we decided to establish a diagnostic test for IR-aAB similar to our IGF1R-aAB assay. IR-aAB are of endocrine importance as they are capable of causing insulin resistance type B. Objective: To compare the prevalence and potential cross-reactivity of IGF1R-aAB and IR-aAB. Methods: Recombinant variants of both receptors were stably expressed in HEK293 cells and used to establish diagnostic autoantibody assays as described (1). A total of 400 samples were obtained from a commercial supplier and analyzed for IGF1R-aAB and IR-aAB presence. Cross-reactivity of positive sera was tested with recombinant IGF1R and IR. Results: A comparable number of sera turned out to be positive for IGF1R-aAB and IR-aAB, respectively, with a prevalence of ~5% each. A fraction of positive samples turned out to react with both the IGF1R and the IR indicating either the presence of multiple specific-aAB isoforms or one type of cross-reacting aAB in a given serum. Clonality and cross-reactivity of the aAB identified are currently under investigation. Conclusion: Our studies demonstrate an unexpected high prevalence of aAB against IGF1R and IR in human sera. In light of case reports on insulin resistance type B, these findings may be of clinical relevance for the present diabetes epidemy, but further studies are needed to test this hypothesis. 1. Minich WB, et al. Journal of Clinical Endocrinology and Metabolism, 2013 (in press, PMID: 23264397).
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Autoantibodies to the insulin- and IGF1-receptor in human sera
Introduction: Autoantibodies (aAB) are characteristic of autoimmune diseases, but may also be found in apparently healthy individuals and precede pathological symptoms. We have recently reported on autoantibodies against the IGF1-receptor (IGF1R-aAB) in control subjects and patients with Graves’ disease (1). The isolated aAB were able to immunoprecipitate the recombinant autoantigen and antagonized IGF1 signaling in vitro. Given the structural similarities between IGF1R and insulin receptor (IR), we decided to establish a diagnostic test for IR-aAB similar to our IGF1R-aAB assay. IR-aAB are of endocrine importance as they are capable of causing insulin resistance type B. Objective: To compare the prevalence and potential cross-reactivity of IGF1R-aAB and IR-aAB. Methods: Recombinant variants of both receptors were stably expressed in HEK293 cells and used to establish diagnostic autoantibody assays as described (1). A total of 400 samples were obtained from a commercial supplier and analyzed for IGF1R-aAB and IR-aAB presence. Cross-reactivity of positive sera was tested with recombinant IGF1R and IR. Results: A comparable number of sera turned out to be positive for IGF1R-aAB and IR-aAB, respectively, with a prevalence of ~5% each. A fraction of positive samples turned out to react with both the IGF1R and the IR indicating either the presence of multiple specific-aAB isoforms or one type of cross-reacting aAB in a given serum. Clonality and cross-reactivity of the aAB identified are currently under investigation. Conclusion: Our studies demonstrate an unexpected high prevalence of aAB against IGF1R and IR in human sera. In light of case reports on insulin resistance type B, these findings may be of clinical relevance for the present diabetes epidemy, but further studies are needed to test this hypothesis. 1. Minich WB, et al. Journal of Clinical Endocrinology and Metabolism, 2013 (in press, PMID: 23264397).